| Scientific
Title of Trial |
Effects of Melothria maderaspatana (Titta kekiri) and Passiflora foetida (Dal batu) dry fruit preparation (topical application) on renal functions of Grade II and III Chronic Kidney Disease (of unknown etiology) patients in North central Province, Sri Lanka |
| |
|
| Public
Title of Trial (in lay language) |
Effects of Melothria maderaspatana (Titta kekiri) and Passiflora foetida (Dal batu) dry fruit preparation (topical application) on renal functions of Grade II and III Chronic Kidney Disease (of unknown etiology) patients in North central Province, Sri Lanka |
| |
|
| Acronym,
if any |
None |
| |
|
| Brief
title, if any |
None |
| |
|
Any
other number(s) assigned to the
trial and issuing authoruty, if any
(eg. sponsor, other trial registry) |
Nil known |
| |
|
| Disease
or Health Condition(s) studied |
Chronic Kidney Disease (of unknown etiology |
| |
|
| What
is the research question being addressed? |
Can Melothria maderaspatana (Titta kekiri) and Passiflora foetida (Dal batu) dry fruit preparation (topical application) improve the renal functions of Grade II and III Chronic Kidney Disease (of unknown etiology) patients in North central province, Sri Lanka
?
|
| |
|
| Study
design |
Single blinded randomized controlled trial |
| |
|
| Intervention(s)
planned |
Paste of dried Melothria maderaspatana (Titta kekiri) and Passiflora foetida (Dal batu) will be applied for 6 hours daily to the big toe of test group for a period of 10 months.
Placebo paste will be applied to the controls in a smiliar manner for the same period |
| |
|
| Inclusion
criteria |
a)Diagnosed patients of having grade II and III CKDu, Normal HbA1C (˂6.5%) and BP˂160/100 mmHg untreated or ˂140/90 mmHg on up to two antihypertensive agents, Persistent albuminuria + eGFR 30- 89 mi/min/1.73m2
b)Age between 20-60 years
c)Permanent residents of Anuradhapura or Polonnaruwa district, for at least 5 years prior to diagnosis as Grade II or III CKDu
|
| |
|
| Exclusion
criteria |
a)Patients with no past history of or current treatment for diabetes mellitus or chronic and/or severe hypertension, snakebite, urological disease of known etiology or glomerulonephritis
b)Patients who are suffering with other chronic diseases or on treatment for any other disease other than CKDu
c)Patients aged less than 20 years and more than 65 years
d)Pregnant and breast feeding mothers
e)Patients who live outside the NCP,are not permanent resident within NCP at least 5 years prior to diagnose as CKDu and residents in GN divisions where WHO is conducting the Study for CKDu
|
| |
|
| Target
number / sample size |
35 |
| |
|
| Primary
outcome(s) |
1.Full blood count
2.Lipid profile
3.Renal profile
4.Liver enzymes-SGPT and SGOT
5.Urine full report including β2 globulin level
6.IFNδ
7.TNFα
8.HSP70
|
| |
|
| Primary outcome(s) -
time of assessment(s) |
10 months |
| |
|
| Secondary
outcome(s) |
None |
| |
|
| Secondary outcome(s) -
time of assessment(s) |
None |
| |
|
| Countries
of recruitment |
Sri Lanka |
| |
|
| Anticipated
start date |
25/04/2011 |
| |
|
| Anticipated
end date |
25/01/2012 |
| |
|
| Recruitment
status |
Pending |
| |
|
| State
of ethics review approval |
Obtained from the Ethical Review Committee of the Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka (14.12.2010) |
| |
|
| Funding
source(s) |
University Grants Commission - Sri Lanka |
| |
|
| Applicant's
Email |
jayasumanalk@yahoo.com |
| |
|
| Approval
Status |
Approved |
| |
|
| Contact
Person for Scientific Queries / Principal investigator |
Dr. M.A.C.S.Jayasumana
Lecturer in Pharmacology, Faculty of Medicine, Rajarata University
Q2, FMAS, Saliyapura, Anuradhapura
0714393989
0252234464
jayasumanalk@yahoo.com |
| |
|
| Primary
Study Sponsor/ Organization |
Faculty of Medicine
University of Rajarata
0252234464
0252234462
www.rajaratauniversity.lk |
| |
|
| Contact
Person for Public Queries |
Dr. M.A.C.S.Jayasumana Lecturer in Pharmacology, Faculty of Medicine, Rajarata University Q2, FMAS, Saliyapura, Anuradhapura 0714393989
0252234462
jayasumanalk@yahoo.com
|
| |
|
| Secondary
Study Sponsor(s), (if any) |
None |